Description: Reprogramming of the Tumor Microenvironment to Create a New Class of Anti-cancer Drugs
cancer (3276) drug (627) tumor microenvironment (6) nashoba biotechnology (1)
Nashoba Biotechnology Reprogramming of the Tumor Microenvironment to Create a New Class of Anti-cancer Drugs
Immunotherapies are revolutionizing cancer treatment and patient outcomes. Approved drugs targeting the immune status of the tumor are already commanding billion-dollar markets. One example of these new medicines is a set of therapies known as immune checkpoint inhibitors (ICIs). These inhibitors reactivate anti-tumor immune responses, for example “releasing the brakes” on T-cells in the suppressive environment of a tumor.
Most significantly, ICIs have achieved clinical results rarely seen before in cancer therapy: long term survival that is remarkably durable in patients in a wide variety of tumor types. However, only a fraction of treated patients achieves these durable responses - generally only 20 to 30%. As a result, there is great interest in increasing the fraction of patients that survive by combining ICIs with other drugs.